Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (7): 675-679.DOI: 10.3969/j.issn.1673-8640.2023.07.011
Previous Articles Next Articles
GUO Jie1, LI Haixia2, LI Xiaoyun1
Received:
2021-03-18
Revised:
2022-03-18
Online:
2023-07-30
Published:
2023-09-18
CLC Number:
GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients[J]. Laboratory Medicine, 2023, 38(7): 675-679.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.07.011
组别 | 例数 | 年龄 | 病理类型 | 肿瘤最大径 | |||||
---|---|---|---|---|---|---|---|---|---|
<45岁/[例(%)] | ≥45岁/[例(%)] | 腺癌/[例(%)] | 非腺癌/[例(%)] | <2 cm/[例(%)] | ≥2 cm/[例(%)] | ||||
高RPR组 | 45 | 22(48.9) | 23(51.1) | 13(28.9) | 32(71.1) | 15(33.3) | 30(66.7) | ||
低RPR组 | 78 | 38(48.7) | 40(51.3) | 67(85.9) | 11(14.1) | 73(93.6) | 5(6.4) | ||
χ2值 | 1.159 | 15.698 | 13.658 | ||||||
P值 | 0.549 | <0.001 | <0.001 |
组别 | 例数 | 年龄 | 病理类型 | 肿瘤最大径 | |||||
---|---|---|---|---|---|---|---|---|---|
<45岁/[例(%)] | ≥45岁/[例(%)] | 腺癌/[例(%)] | 非腺癌/[例(%)] | <2 cm/[例(%)] | ≥2 cm/[例(%)] | ||||
高RPR组 | 45 | 22(48.9) | 23(51.1) | 13(28.9) | 32(71.1) | 15(33.3) | 30(66.7) | ||
低RPR组 | 78 | 38(48.7) | 40(51.3) | 67(85.9) | 11(14.1) | 73(93.6) | 5(6.4) | ||
χ2值 | 1.159 | 15.698 | 13.658 | ||||||
P值 | 0.549 | <0.001 | <0.001 |
临床特征 | 例数 | 5年生存/[例(%)] | χ2值 | P值 | 临床特征 | 例数 | 5年生存/[例(%)] | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|
年龄 | 分化程度 | ||||||||
<45岁 | 60 | 38(63.3) | 1.185 | 0.538 | G1级 | 84 | 70(83.3) | 15.635 | <0.001 |
≥45岁 | 63 | 37(58.7) | G2级 | 30 | 4(13.3) | ||||
病理类型 | G3级 | 9 | 1(11.1) | ||||||
腺癌 | 80 | 68(85.0) | 18.658 | <0.001 | 病理级别 | ||||
非腺癌 | 43 | 7(16.2) | 高 | 103 | 68(66.1) | 17.589 | <0.001 | ||
肿瘤最大径 | 低 | 20 | 7(35.0) | ||||||
<2 cm | 88 | 60(68.1) | 18.547 | <0.001 | 淋巴转移 | ||||
≥2 cm | 35 | 15(42.8) | 无 | 100 | 70(70.0) | 14.587 | <0.001 | ||
FIGO分期 | 有 | 23 | 5(21.7) | ||||||
Ⅰ/Ⅱ期 | 83 | 62(74.6) | 18.658 | <0.001 | 复发 | ||||
Ⅲ期 | 40 | 13(32.5) | 无 | 110 | 72(65.4) | 30.748 | <0.001 | ||
淋巴血管间隙浸润 | 有 | 13 | 3(23.1) | ||||||
无浸润 | 92 | 65(70.6) | 16.358 | <0.001 | RPR | ||||
有浸润 | 31 | 10(32.2) | 高 | 45 | 18(40.0) | 28.896 | <0.001 | ||
低 | 78 | 47(73.1) |
临床特征 | 例数 | 5年生存/[例(%)] | χ2值 | P值 | 临床特征 | 例数 | 5年生存/[例(%)] | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|
年龄 | 分化程度 | ||||||||
<45岁 | 60 | 38(63.3) | 1.185 | 0.538 | G1级 | 84 | 70(83.3) | 15.635 | <0.001 |
≥45岁 | 63 | 37(58.7) | G2级 | 30 | 4(13.3) | ||||
病理类型 | G3级 | 9 | 1(11.1) | ||||||
腺癌 | 80 | 68(85.0) | 18.658 | <0.001 | 病理级别 | ||||
非腺癌 | 43 | 7(16.2) | 高 | 103 | 68(66.1) | 17.589 | <0.001 | ||
肿瘤最大径 | 低 | 20 | 7(35.0) | ||||||
<2 cm | 88 | 60(68.1) | 18.547 | <0.001 | 淋巴转移 | ||||
≥2 cm | 35 | 15(42.8) | 无 | 100 | 70(70.0) | 14.587 | <0.001 | ||
FIGO分期 | 有 | 23 | 5(21.7) | ||||||
Ⅰ/Ⅱ期 | 83 | 62(74.6) | 18.658 | <0.001 | 复发 | ||||
Ⅲ期 | 40 | 13(32.5) | 无 | 110 | 72(65.4) | 30.748 | <0.001 | ||
淋巴血管间隙浸润 | 有 | 13 | 3(23.1) | ||||||
无浸润 | 92 | 65(70.6) | 16.358 | <0.001 | RPR | ||||
有浸润 | 31 | 10(32.2) | 高 | 45 | 18(40.0) | 28.896 | <0.001 | ||
低 | 78 | 47(73.1) |
自变量 | 回归系数 | 标准误 | Wald值 | P值 | 风险比(95%可信区间) |
---|---|---|---|---|---|
病理类型(非腺癌与腺癌) | 0.817 | 0.268 | 19.657 | <0.001 | 2.26(1.34~3.83) |
复发(有与无) | 0.638 | 0.227 | 20.574 | <0.001 | 1.89(1.21~2.95) |
FIGO分期(Ⅲ期与Ⅰ~Ⅱ期) | 1.527 | 0.524 | 15.789 | <0.001 | 4.60(1.65~12.86) |
RPR(高RPR与低RPR) | 1.759 | 0.436 | 23.789 | <0.001 | 5.81(2.47~13.65) |
自变量 | 回归系数 | 标准误 | Wald值 | P值 | 风险比(95%可信区间) |
---|---|---|---|---|---|
病理类型(非腺癌与腺癌) | 0.817 | 0.268 | 19.657 | <0.001 | 2.26(1.34~3.83) |
复发(有与无) | 0.638 | 0.227 | 20.574 | <0.001 | 1.89(1.21~2.95) |
FIGO分期(Ⅲ期与Ⅰ~Ⅱ期) | 1.527 | 0.524 | 15.789 | <0.001 | 4.60(1.65~12.86) |
RPR(高RPR与低RPR) | 1.759 | 0.436 | 23.789 | <0.001 | 5.81(2.47~13.65) |
[1] | 刘坤, 李英, 齐红双, 等. 血清CEA、HE4、CA199、CA153、CA125水平联合检测在妇科恶性肿瘤诊断中的临床意义[J]. 实验与检验医学, 2020, 38(2):326-328. |
[2] |
DOHERTY M T, SANNI O B, COLEMAN H G, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia:a systematic review and meta-analysis[J]. PLoS One, 2020, 15(4):e0232231.
DOI URL |
[3] | 王丽娟, 贺全勤, 赵盼. P53蛋白、Rictor蛋白表达水平与子宫内膜癌病理特征的关系[J]. 实验与检验医学, 2020, 38(3):512-515. |
[4] | 韩倩, 时光, 赵瑞华. 血清CA125在子宫内膜异位症的临床应用价值[J]. 中国妇产科临床杂志, 2019, 20(1):94-96. |
[5] |
PEDRAZZANI C, TRIPEPI M, TURRI G, et al. Prognostic value of red cell distribution width(RDW)in colorectal cancer. Results from a single-center cohort on 591 patients[J]. Sci Rep, 2020, 10(1):1072.
DOI |
[6] |
XU W Y, YANG X B, WANG W Q, et al. Prognostic impact of the red cell distribution width in esophageal cancer patients:a systematic review and meta-analysis[J]. World J Gastroenterol, 2018, 24(19):2120-2129.
DOI URL |
[7] |
SHOTA S, SAITO H, KONO Y, et al. Prognostic significance of pre- and post-operative red-cell distribution width in patients with gastric cancer[J]. J Gastrointest Surg, 2020, 24(5):1010-1017.
DOI PMID |
[8] |
MA W, MAO S, BAO M, et al. Prognostic significance of red cell distribution width in bladder cancer[J]. Transl Androl Urol, 2020, 9(2):295-302.
DOI PMID |
[9] | 孙影, 王晶, 刘天伯, 等. 血小板升高与妇科恶性肿瘤的影响[J]. 现代生物医学进展, 2019, 19(3):580-582. |
[10] |
TAKEUCHI H, ABE M, TAKUMI Y, et al. Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer[J]. Sci Rep, 2019, 9(1):3033.
DOI PMID |
[11] |
YILMAZ H, YILMAZ A, DEMIRA G. Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer[J]. Future Oncol, 2021, 17(29):3853-3864.
DOI PMID |
[12] | 刘妍, 张泗扬, 张昌文, 等. 术前红细胞分布宽度与血小板比值对RP术后接受内分泌治疗患者预后的预测价值[J]. 中华泌尿外科杂志, 2021, 42(8):586-591. |
[13] |
HU L, LI M, DING Y, et al. Prognostic value of RDW in cancers:a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(9):16027-16035.
DOI URL |
[14] |
TAKEUCHI H, NODA D, ABE M, et al. Evaluating the platelet distribution width-to-plateletcrit ratio as a prognostic marker for patients with breast cancer[J]. Anticancer Res, 2020, 40(7):3947-3952.
DOI PMID |
[15] |
OCHOWSKI M, CHAUBISKA-FENDLER J, OCHOWSKA B, et al. Prognostic value of red blood cell distribution width-standard deviation(RDW-SD)in patients operated on due to non-small cell lung cancer[J]. J Thorac Dis, 2020, 12(3):773-781.
DOI URL |
[16] |
HUANG T B, ZHU L Y, ZHOU G C, et al. Pre-treatment red blood cell distribution width as a predictor of clinically significant prostate cancer[J]. Int Urol Nephrol, 2021, 53(9):1765-1771.
DOI |
[17] | ZHOU Y, LI X, LU Z, et al. Prognostic significance of red blood cell distribution width in gastrointestinal cancers:a meta-analysis[J]. Medicine(Baltimore), 2020, 99(16):e19588. |
[18] |
IDE S, TOIYAMA Y, OKUGAWA Y, et al. Clinical significance of an increased red blood cell distribution width in patients with rectal cancer undergoing chemoradiotherapy followed by surgery[J]. Surg Today, 2020, 50(6):551-559.
DOI PMID |
[19] |
CHEN J L, WU J N, LV X D, et al. The value of red blood cell distribution width,neutrophil-to-lymphocyte ratio,and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer[J]. PLoS One, 2020, 15(8):e0237947.
DOI URL |
[20] |
ZHANG H, LIANG K, KE L, et al. Clinical application of red cell distribution width,mean platelet volume,and cancer antigen 125 detection in endometrial cancer[J]. J Clin Lab Anal, 2020, 34(8):e23309.
DOI URL |
[21] |
YILMAZ A, MIRILI C, TEKIN S B, et al. The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT:a retrospective study[J]. Ir J Med Sci, 2020, 189(1):91-102.
DOI |
[22] | TEKIN Y K, TEKIN G. Mean Platelet volume-to-platelet count ratio,mean platelet volume-to-lymphocyte ratio,and red blood cell distribution width-platelet count ratio as markers of inflammation in patients with ascending thoracic aortic aneurysm[J]. Braz J Cardiovasc Surg, 2020, 35(2):175-180. |
[23] |
LEE H S, JUNG E J, KIM J M, et al. The usefulness of red blood cell distribution width and its ratio with platelet count in breast cancer after surgery and adjuvant treatment:a retrospective study[J]. Gland Surg, 2022, 11(12):1864-1873.
DOI URL |
[24] |
SU Y C, WEN S C, LI C C, et al. Low hemoglobin-to-red cell distribution width ratio is associated with disease progression and poor prognosis in upper tract urothelial carcinoma[J]. Biomedicines, 2021, 9(6):672.
DOI URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||